Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double Blind Evaluation of Different One-Year Boosts After Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults

X
Trial Profile

Randomized, Double Blind Evaluation of Different One-Year Boosts After Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV gp120 vaccine (Primary) ; HIV vaccine vCP1521 (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Jun 2023 Status changed from active, no longer recruiting to completed according to results published in the AIDS.
    • 01 Jun 2023 Results assessing impact of an additional boost to the RV144 vaccine regimen on antibody effector function and durability published in the AIDS
    • 25 Mar 2021 Planned End Date changed from 1 May 2021 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top